Autopsy report · NCT03450707

Thiamine as a Metabolic Resuscitator After Cardiac Arrest

“DSMB recommendation based on differing mortality in a subgroup analysis”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 3 years 9 months before it stopped.
• 93 participants enrolled.
• Results were posted on the registry 1 year 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Michael Donnino

Sponsor type

University, hospital or other

Conditions

Cardiac Arrest

Interventions

Thiamine 500 mg IV; Placebo

Participants

93

Sites

1

Countries

United States

Trials that died the same way

• Preventing Adverse Incisional Outcomes at Cesarean Multicenter Trial
  “DSMB recommendation following interim analysis” (71% match in meaning)
• Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil
  “DSMB recommendation based on programmed interim analysis.” (69% match in meaning)
• Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO
  “DSMB recommendation (futility)” (59% match in meaning)
• A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy
  “Upon recommendation of DSMB” (59% match in meaning)
• Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis
  “The study treminated early according to DSMB recommendantions” (55% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.